Skip to main content
. Author manuscript; available in PMC: 2012 Jun 11.
Published in final edited form as: Eur J Pharmacol. 2011 Jan 3;660(1):125–130. doi: 10.1016/j.ejphar.2010.12.020

Figure 3.

Figure 3

Schematic representation of melanocortin receptor agonist-selective signaling. Agonist I and II exhibit different efficacies in pathway A and B. Agonist I is a full agonist for pathway A and B. Agonist II is a full agonist for only pathway B.